Microbiota-gut-brain axis and its affect inflammatory bowel disease: Pathophysiological concepts and insights for clinicians

Emanuele Sinagra, Erika Utzeri, Gaetano Cristian Morreale, Carlo Fabbri, Fabio Pace, Andrea Anderloni

ORCID number: Emanuele Sinagra (0000-0002-8528-0384); Erika Utzeri (0000-0002-5125-118X); Gaetano Cristian Morreale (0000-0001-8954-7819); Carlo Fabbri (0000-0003-2430-7149); Fabio Pace (0000-0002-8727-5757); Andrea Anderloni (0000-0002-1021-0031).

Author contributions: Sinagra E designed the study; Sinagra E, Utzeri E, and Morreale GC wrote the paper; Pace F and Jones R contributed to the revision of the manuscript; Anderloni A supervised the work.

Conflict-of-interest statement: All the authors declare that this research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors, and thus there is no conflict of interest regarding this paper.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: December 30, 2019

Abstract

Despite the bi-directional interaction between gut microbiota and the brain not being fully understood, there is increasing evidence arising from animal and human studies that show how this intricate relationship may facilitate inflammatory bowel disease (IBD) pathogenesis, with consequent important implications on the possibility to improve the clinical outcomes of the diseases themselves, by acting on the different components of this system, mainly by modifying the microbiota. With the emergence of precision medicine, strategies in which patients with IBD might be categorized other than for standard gut symptom complexes could offer the opportunity to tailor therapies to individual patients. The aim of this narrative review is to elaborate on the concept of the gut-brain-microbiota axis and its clinical significance regarding IBD on the basis of recent scientific literature, and finally to focus on pharmacological therapies that could allow us to favorably modify the function of this complex system.

Key words: Irritable bowel syndrome; Inflammatory bowel disease; Gut-brain axis; Therapy
INTRODUCTION

The complex interplay between gut microbiota and the brain, and vice versa, has recently become not only the focus of neuroscience, but also the start point for research regarding many diseases such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS)\(^1\)-\(^4\).

The bi-directional interaction between gut microbiota and the brain is not completely understood. Nonetheless, there is increasing evidence arising from animal and human studies that show how this intricate relationship may contribute to the pathogenesis of IBD, with consequent important implications for the possibility to improve the clinical outcomes of the diseases themselves by acting on the different components of this axis\(^5\)-\(^7\).

The aim of this narrative review is to elaborate on the concept of the gut-brain-microbiota axis and its clinical significance regarding IBD on the basis of recent scientific literature, and finally to focus on pharmacological therapies that could allow us to favorably modify the function of this complex system.

WHAT IS THE GUT-BRAIN-MICROBIOTA AXIS?

While the idea that the brain can alter intestinal functions has long been recognized and accepted, the concept that signals from the gut can have effects on mood, behavior and cognitive function is less widely accepted.

First of all, it should be highlighted that the digestive system is very complex. This is due to the fact that it represents not only a surface of about 300 square meters for absorption, but it also a very complex hormonal system that produces more than thirty hormones, and of a very complex immune system, since it contains 60%-70% of a person’s immune cells. Furthermore, it is an extremely innervated system, with an extensive intrinsic nervous system, namely, the enteric nervous system (ENS), that controls bowel function even though it is completely separate from the central nervous system (CNS)\(^8\)-\(^9\).

Finally, our digestive system contains various microorganisms [about 10 (14)], such as bacteria, fungi, parasites, and viruses, and more than 100 million bacteria reside in the human gastrointestinal tract, establishing a mutually beneficial symbiotic state with the human organism. The gut microbiota controls the development and homeostasis of the host by acting on human metabolism and immune function, and also by controlling xenobiotic and drug metabolism, maintaining the structural integrity of the gut mucosal barrier, regulating the motility of the gut and promoting protection against pathogens.

The gut-brain-microbiota axis is defined as a two-way communication system that allows intestinal microbes to communicate with the brain and vice versa. This system,
which has not been entirely explored, is based on neural, endocrine, immunological and metabolic pathways\textsuperscript{[13,14].} This network contains several levels of communication and complex interplay, shown in Figure 1, namely\textsuperscript{[12]:} (1) Gut microbiota, acting bi-directionally in this system through several mechanisms; (2) The ENS, which is made up of interneurons, sensory neurons, motor neurons, and neurotransmitters; (3) The autonomic nervous system (ANS), the pivotal modulator of the ENS; (4) The enteric-endocrine and immune signaling agents; (5) The neuroendocrine signaling network mediated by the hypothalamic-pituitary-adrenal (HPA) axis, which is activated by the integrative reactions of specific centers in the CNS, and represents a central integrative system mandatory for the successful physiological adaptation of our organism to stress; and (6) The CNS, includes the hypothalamus, amygdala, and hippocampus and their interaction with emotional centers localized within the limbic system, which are mainly involved in the control of body reaction in response to stress.

In this system, in presence of a stressor or perturbing agent, inflammatory cytokines as IL1-beta, IL6 and TNF-\alpha, several chemical substances, such as short chain fatty acids (SCFA), and microbial substances, can modify the ANS causing the secretion of cortisol and adrenaline from the adrenal glands through CRF and ACTH-dependent pathways\textsuperscript{[19].}

Gut microbiota and neuroactive products (released from the entericendocrine and immune system) impair intestinal secretion and compromise the integrity of intestinal mucosa in response to perturbing agents\textsuperscript{[19].} Therefore, several stressors render the intestinal mucosa more permeable to bacterial cytotoxins and neurotransmitters (norepinephrine), and cause the development of inflammation. In all these situations associated with stress, microbial agents translocate from the intestinal lumen into the systemic circulation, affecting the central and peripheral organs\textsuperscript{[13].}

Efferent communication between the CNS and the gut mucosa include the vagal nerve and pelvic parasympathetic efferents and postganglionic sympathetic neurons\textsuperscript{[13,14].}

Furthermore, the stress-induced activation of the HPA results in an enhanced production of corticosteroids from the adrenal glands\textsuperscript{[13,15,16].} Furthermore, the sympathetic autonomic system also becomes activated, thus leading to the secretion of catecholamines such as epinephrine and norepinephrine\textsuperscript{[13,17].}

**Gut microbiota and its effect on the gut-brain axis**

Gut microbiota is one of the densest, and quickly developing bacterial ecosystems and is characterised by great biodiversity. The intestinal microbiome, which is its collective genome, is an adaptive entity that varies in response to food intake, daily habits and surroundings, providing the host with an extra metabolic plasticity as well as functions that humans have not developed\textsuperscript{[18,19].}

Several experimental approaches have been used to study the modulatory effect of gut microbiota on gut-brain interactions, including gut microbial manipulation with antibiotics\textsuperscript{[20,21]}, fecal microbial transplantation\textsuperscript{[21,22]}, and the use of germ-free animal models\textsuperscript{[23].}

For a recent overview of the complex mechanism of the microbiota-gut-brain axis, the reader is referred to the work by Carabotti et al\textsuperscript{[23].} In summary, microbiota modulation of the intestinal barrier is an important mechanism, with a net effect of strengthening tight junction integrity\textsuperscript{[13,24].} Gut microbiota is also involved in hippocampal neurogenesis and expression in hypothalamic genes involved in synaptic plasticity\textsuperscript{[25].} Furthermore, gut microbiota modulates pain perception and gut motility by acting on enteric sensory afferents\textsuperscript{[26]} through the production of local neurotransmitters, such as gamma-aminobutyric acid, serotonin, nitric oxide, melatonin, catecholamine, histamine, acetylcholine and hydroxide sulfate\textsuperscript{[27-29]}, but also neurotrophic factors (brain-derived neurotrophic factor)\textsuperscript{[30].} Finally, microbiota affects the immune regulation of the intestinal mucosa by means of several mechanisms, such as the increase of substance P in the ENS, and the down-regulation of proteases\textsuperscript{[30,31]}, and it produces small molecules, such as SCFA involved in many neural processes, such as the stimulation of sympathetic activity and the release of serotonin\textsuperscript{[32].}

On the other hand, gut microbiota is affected by the brain through the secretion of signaling molecules (i.e., catecholamines and gamma-aminobutyric acid) by neurons, immune and enterocromaffin cells, which may affect the microbiota itself\textsuperscript{[22].} Furthermore, controlled by the brain, also intestinal motility and permeability, as well as the production of mucus, acid, bicarbonates and fluids, are modulated through direct action (host-enteric microbiota signaling) and indirectly (by the actions of the HPA axis or by variations of the composition, and therefore of the function, of microbiota)\textsuperscript{[32,29].}
The gut-brain-microbiota axis is defined as a two-way communication system that allows intestinal microbes to communicate with the brain and vice versa. The multiple inter-related structural networks of the central nervous system regulates autonomic nervous system input that alter gut microbial composition and function indirectly by modulating the microbial environment in the gut, and by affecting also the immune response. On the other hand, the gut microbiota can interact with the brain indirectly via gut-derived metabolites by acting on afferent vagal and/or spinal nerve endings, or directly via microbe-generated signals which act on enteroendocrine cells. Furthermore, the neuroendocrine signaling network mediated by the hypothalamic-pituitary-adrenal axis, which is activated by the integrative reactions of specific centers in the central nervous system, represents a central integrative system mandatory for the successful physiological adaptation of our organism to different stressors.

WHAT IS THE CLINICAL SIGNIFICANCE OF THE CHANGES TO THE GUT-BRAIN-AXIS MICROBIOTA IN INFLAMMATORY BOWEL DISEASE?

IBD pathogenesis is only partly understood, and some studies highlight a link with intestinal microbiota. In particular, the bidirectional relationship of the gut-brain axis, seems to be central also in the onset and development of IBD.

How is dysbiosis involved in the pathogenesis of IBD?

Similar to IBS, there is an alteration of the balance between microbiota and the gastrointestinal tract, with the onset of dysbiosis[33,34]. The dysbiosis present in patients with IBD is characterized by reduced bacterial diversity, reduction of Bacteroidetes and Firmicutes, and an increase in Proteobacteria[35], in particular Escherichia coli[36]. Other species such as Faecalibacterium prausnitzii and Roseburia hominis are selectively reduced in patients with IBD[37,38]. Patients with active IBD have a lower abundance of intestinal flora than patients in remission[39]. An alteration of intestinal bacterial flora in genetically susceptible individuals can lead to abnormal intestinal immune responses and intestinal imbalance[40]. Interestingly, antibiotics may have some effect on IBD symptoms[41], and it is known that the predisposing genes involved in IBD pathogenesis are those with an important role in recognition of pathogen microbes[42] or in tolerance of commensals.

Furthermore, as discussed below, a confirmation of the influence of the microbiota on IBD pathogenesis is given by the benefits of using probiotics or prebiotics for these patients. The use of selected probiotics is effective in inducing and maintaining remission in ulcerative colitis (UC)[43] and in the treatment of pouchitis[44], whereas the use of prebiotics has been shown to be successful in reducing inflammation and bringing about remission in UC[45]. Data are far less impressive in Crohn's disease (CD)[46,47]. Faecal transplantation also appears to produce a modest increase in remission rates in patients with IBD[48].

How inflammation could modify the function of the gut-brain microbiota axis?

Lessons from animal and human studies

IBD results in an inflammatory reaction in the brain, the activation of the hypothalamic-pituitary-adrenal axis and parts of the brain involved in behavioral...
alteration, an alteration of the blood-brain barrier and an intestinal-microbiota imbalance. Pro-inflammatory cytokines play a crucial role in the IBD pathogenesis and interact with the CNS directly by means of the blood-brain barrier or via the vagus nerve. Such inflammatory pathway via cytokines works by dysregulating HPA by over-activating microglia, altering neuroplasticity, and inducing structural and functional changes in the brain. Several mouse studies showed that cytokines determine the activation of astrocytes, thus affecting neural functions during the processes of inflammation during the period between behavioral effects such as depression. These in fact can affect the HPA axis, activating it and consequently causing an increase in glucocorticoids involved in pathogenesis of depression.

Other animal models have been used to investigate the relationship between gastrointestinal disorders and psychological manifestations. For example, maternal separation is a stressor induced in the early stages of life. Other examples of chronic stressors are housing problems and overcrowding, such stressors can induce gastrointestinal dysfunction or increase susceptibility to chemically induced colitis. These studies may explain the link between stress and gastrointestinal disorders and therefore IBS-like symptoms in patients with IBD, although not entirely specific to IBD.

In further animal studies, the mechanism of immune activation in the gut and its interaction with the central nervous system were explained. There are several murine models of IBD, which include, for example, the use of dextran sodium sulfate (DSS), the colorectal instillation of dinitrobenzenic sulfonic acid and 2, 4, 6-trinitrobenzenesulfonic acid (TNBS), that show an increase in hippocampal, cerebral and hypothalamic pro-inflammatory cytokines. Indeed, the disruption of the blood-brain barrier and the leukocyte infiltration of the brain following colic inflammation leaves the CNS vulnerable to inflammation mediators and to substances of bacterial and viral derivation.

**What is the role of the stress, considered to be a perturbing agent of brain-gut-microbiota axis, in IBD?**

Stress may have a deleterious effect on IBD, through several pathways, as reviewed by Bonaz et al., including the activation of mast cells and the CNS and the inhibition of the vagus nerve on inflammatory pathways, decreasing its anti-inflammatory effects and increasing sympathetic tone; this may lead to the inhibition of immune defenses and development/increase of intestinal inflammation. It has been shown that stress induces an imbalance in the ANS in patients with IBD and a vagal dysfunction in patients with UC. For patients with IBD there is a correlation between ANS imbalance, psychological disorders and pro-inflammatory profiles.

Important factors are also the effect of early childhood stressful events on colitis (the HPA axis is determined by early childhood events, and neonatal inflammatory stimuli exert long-term changes on HPA activity) and the impact of depression on exacerbation of colitis possibly through proinflammatory cytokines. Last, but not least, stress and CRF increase intestinal permeability as observed in mouse models, with passage of intestinal bacteria through the epithelial barrier. In patients with IBD, changes in stress-mediated intestinal microbiota may create susceptibility to infection and alter neural activity in stress-sensitive areas of the brain.

Dysbiosis can directly affect mental health in patients with IBD. Behavioral disorders such as stress, anxiety and depression may change the composition of the intestinal flora and may influence the activity and recurrence of CD as demonstrated by numerous studies. Recent studies have highlighted that the most involved mechanisms in stress signaling, on the cellular level, are endoplasmic reticulum stress, oxidative stress and hypoxia. The subsequent host cellular response to these mechanisms interact with gut microbiota, thus modifying the microbiological microenvironment of the gastrointestinal tract.

Indeed, exposing mice to stressful stimuli resulted in the alteration of gut microbiota by reducing anti-inflammatory bacteria, in particular Lactobacillus and Lachnospiraceae. Furthermore, psychological stress reduces the biosynthesis and metabolism of short chain fatty acids, which may increase susceptibility toward intestinal inflammation and further IBD.

It is now known that IBD is associated with psychological symptoms such as anxiety and depression, prevalent during active disease states and, as also observed in animal models of IBD, there are no differences in occurrence of CD and UC. Mood disorders may also influence the course of IBD because it is hypothesized that stress may be a risk factor for recurrence for patients of this type. Probably, the depressive behavior observed in patients with IBD constitutes a comorbidity, which worsens the state of intestinal disease.

In the murine models of DSS colitis, induction of depression with olfactory bulbectomy or intracerebroventricular injection of reserpine was associated with the...
reactivation of inflammation in mice with quiescent colitis, with effects mediated by the increase of pro-inflammatory cytokines\cite{88}. In contrast, the administration of tricyclic antidepressants prevented the reactivation of colitis for depressed mice but not in mice without depression\cite{87}. As previously mentioned, in many studies conducted on adults and children it is clear that both UC and CD are associated with a higher incidence of psychological symptoms\cite{89}, with an association between disease and mood. These data are confirmed by a recent systematic review, with equal rates in both sexes, but slightly higher for CD than for UC\cite{90}. Depression and anxiety are 2 to 3 times higher in patients with IBD than in the general population, affecting respectively 25% and 30% of people with IBD\cite{91}. Patients with IBD who suffer from psychiatric illness have a reduced chance of remission, and the condition worsens over a longer period of time\cite{90}. An increased risk of psychiatric disorders is also observed in adolescents and children with IBD\cite{92}. Adolescent patients with IBD are more likely to have mild behavioral and cognitive disturbances, particularly verbal memory loss\cite{93}. Active IBD correlates significantly with increased psychological disorders\cite{94,95} and the highest pain scores are strong predictors of depression in UC and CD\cite{96}. In patients with UC, depression is usually diagnosed in the year before the onset of disease symptoms, while for patients with CD depression follows the diagnosis of the disease\cite{97}. Being female is also a predictor of anxiety and depression with IBD\cite{98,99}, with IBD having a bigger effect on health-related quality of life\cite{100} and greater concomitance of symptoms similar to IBS\cite{101}. The manifestation of mood disorders by IBD patients correlates with a greater risk of requiring surgery and of incurring secondary FGID development\cite{102}.

In the Manitoba IBD study, a cohort of patients with IBD monitored every 6 mo, and with annual interviews over a period of 12 years, psychological disorders were highlighted as a major factor in health perception for the IBD cohort\cite{103}. In another study involving 600 subjects with IBD, using health problem surveys conducted quarterly for 1 year, about 50% of patients showed a certain type of stress, most frequently family stress, followed by work or school and finance related stress\cite{104}. It was observed that psychological factors, important life events, high anxiety and highly negative feelings during the previous 3 mo were closely associated with the occurrence of a flare up. Targownik et al\cite{105} observed that perceived stress correlated closely with the symptoms of active disease, but without any correlation between the symptom scores and the degree of inflammation associated with CD, and only a weak correlation associated with UC, concluding that there may be an association between the perceived stress and the symptoms of IBD regardless of inflammatory activity.

Furthermore, IBD also influence the volume of gray matter and the size of the brain according to an MRI study, which observed that patients with CD displayed a decrease in the volume of gray matter in the frontal cortex and in the cortex of the anterior cingulate\cite{106}. Interestingly, Gracie et al\cite{107} recently found evidence in a 24 mo study of CD or UC patients of a reciprocal relationship between IBD occurrence or severity and psychological illness, thus concluding that IBD patients’ psychological health should be monitored.

**WHAT THERAPEUTIC INTERVENTIONS ARE THERE THAT TARGET THE GUT-BRAIN-MICROBIOTA AXIS WHEN IBD OCCURS?**

**Manipulation of gut microbiota**

Since gut microflora may trigger changes leading to IBD, the manipulation of the microbiota through administration of probiotics, prebiotics, synbiotics, dietary modifications and faecal transplantation are potentially promising approaches to gastrointestinal diseases, including IBD\cite{108,109}.

The literature concerning the use of probiotics for the bringing about and preservation of CD remission is diverse in content and hard to interpret. The reasons for such heterogeneity are several: The different probiotics (strain and doses) used, the differences in study duration, the features of the included patients, and the measured endpoints\cite{110,112}. Furthermore, two meta-analyses\cite{112,114} on the effects of probiotics as a group indicated that their impact was no different from placebo.

With regard to UC, it was shown that the use of Escherichia coli Nissle 1917 strain for patients with UC was effective in maintaining remission as mesalazine therapy alone\cite{111,114}.

Successively, Shadnoush et al\cite{113} showed that consuming yogurt containing Bifidobacterium and Lactobacillus may contribute to the maintenance of the homeostasis in gastrointestinal tract and regulate pro- and anti-inflammatory
responses by the intestinal immune cells and may therefore be advised for patients with active IBD. Similarly, the consumption of Bifidobacteria-fermented milk was observed to exert a possible preventive effect on the recurrence of UC and helped to maintain its remission, while the use of combined treatment with Lactobacillus and mesalazine was found to be more effective in prolonging the relapse-free period than treatment with Lactobacillus GG and mesalazine alone for UC patients.

With regard to pouchitis, VSL3, a probiotic preparation containing 8 strains, when used for patients with pouchitis in small controlled trials and it was found to be beneficial for the primary and secondary prevention of pouchitis.

In contrast to the many studies on probiotics, there have been few studies (with conflicting results) that have addressed the role of prebiotics in encouraging the increase in number and/or activity of one or a limited class of bacteria in the gastrointestinal tract with a resulting improvement in the host’s IBD.

In these studies it was reported that increasing the SCFA concentration in the gut (as a result of the consumption of prebiotics) enhances growth of protective bacteria (symbionts), while limiting the growth of pathobionts.

With regards to symbiotics, they influence the development of beneficial intestinal microflora through the use of probiotics, whereas prebiotics inhibit the growth of pathogenic bacteria.

Finally, we move on to psychobiotics, which can be defined as live bacteria (probiotics) that “confer mental health benefits through interactions with commensal gut bacteria.” Such probiotics have an effect on emotional, cognitive, systemic, and neural variables that determine psychological well-being. Both rodent and human studies, as reviewed by Sarkar et al., showed the complex interactions between the modulation of gut microbiota with the gut-brain axis.

For IBD, data about the use of psychobiotics are limited to animal models, where they affected the gut-brain axis by modifying the immune system.

Other therapeutic interventions targeting the gut-brain axis in cases of inflammatory bowel diseases

Several factors interplay including triggering of the brain’s inflammation response system, the hypothalamic-pituitary-adrenal axis, and areas of the brain are associated with altered behaviour, changes in the integrity of the blood brain barrier, and an emerging role of gut microbiota and the response to probiotics in IBD cases. It is advised that IBD patients be monitored for psychological problems and treated appropriately as intervening can better quality of life and could diminish rates of relapse. Several evidence-based treatments are available for most causes of psychological distress in IBD patients, the most widely accepted being rooted in cognitive behavioral theory.

Mindfulness interventions do not seem to impact disease activity and other disease-related factors in patients with UC or CD. These findings are consistent with data from other psychosocial interventions which did not demonstrate a positive impact on IBD clinical course. There is limited preliminary evidence that mindfulness interventions may have a positive impact on some inflammatory markers.

Patients want their gastroenterologist to discuss psychological issues during routine visits, and many are open to or desire referral to qualified mental health providers for concurrent treatment.

An alternative therapy to conventional anti-TNF-α treatment, based on gut-brain interactions, is stimulation of the cholinergic anti-inflammatory pathway, either pharmacologically or through vagal nerve stimulation or nutrition, as reviewed by Bonaz et al. For example, galantamine is a centrally acting acetylcholinesterase inhibitor and a positive allosteric modulator of nicotinic receptors, including alpha7nACHR, which stimulates efferent VN activity, suppresses serum TNF-α and IL-6 levels. In contrast, other drugs evaluated in this setting, i.e., CNI-1493, which is a tetravalent guanylylhydrazone that inhibits production of proinflammatory cytokines in macrophages, and GTS-21, an alpha7nACHR agonist, were both associated with markedly reduced TNF-α, IL-6, and IL-1ra plasma concentrations. Finally, another alpha7nACHR agonist, AR-R17779, has been used with success in a mouse model of postoperative ileus.

CONCLUSION

In conclusion, lines of communication between the brain and gut have a crucial role in the biology, clinical manifestations and clinical outcomes of gut diseases such as IBD. The central pathways through which this interplay is mediated are neural and...
In the era of patient-centered health care, treating the "brain" is as important as the "gut" for diseases. It seems to be with good reason that experts have said "as we enter a new interplay, with the potential to disrupt the proximal drivers of these important microbiota could hold the key to effectively uncoupling pathological gut-brain patients. In particular, anti-cytokine therapy or efforts to manipulate the intestinal symptom complexes might offer the opportunity to tailor therapies to individual strategies in which patients with IBD might be classified beyond standard gut scoring tools in patients with gut diseases. With the emergence of precision medicine, envisage the emergence of new diagnostic criteria, biomarkers and psychological an important target of the stress response. What effect these insights will have on these pathways as it specifically interacts with nerves, the luminal microbiota and it is patients. Overall, the mucosal immune system is potentially the key gatekeeper of responsible for instigating brain pathology and, particularly, mood disorders in other by aberrant brain function, and conversely, gut homeostasis disorder being.

REFERENCES

1. Schmidt C. Mental health: thinking from the gut. Nature 2015; 518: S12-S15 [PMID: 25715275 DOI: 10.1038/518S13a]
2. Smith PA. The tantalizing links between gut microbes and the brain. Nature 2015; 526: 312-314 [PMID: 26469024 DOI: 10.1038/526312a]
3. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 2014; 34: 15490-15496 [PMID: 25392516 DOI: 10.1523/JNEUROSCI.17299]
4. Wang HX, Wang YP. Gut Microbiota-brain Axis. Clin Med J (Engl) 2016; 129: 2373-2380 [PMID: 27647198 DOI: 10.4103/0166-6999.190667]
5. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwed PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2015; 62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
6. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500-1512 [PMID: 24583088 DOI: 10.1053/j.gastro.2014.02.037]
7. Ford AC, Quigley EM, Lacy BE, Lenzo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-61, quiz 1546, 1562 [PMID: 25070051 DOI: 10.1038/ajg.2014.202]
8. Bayliss WM, Starling EH. The movements and innervation of the small intestine. J Physiol 1899; 24: 99-145 [PMID: 16992487 DOI: 10.1113/jphysiol.1899.sp000752]
9. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 2012; 9: 286-294 [PMID: 22392290 DOI: 10.1038/norgastro.2012.32]
10. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-314 [PMID: 19404271 DOI: 10.1038/nrgastro.2009.25]
11. El Aidy S, Dinan TG, Cryan JF. Gut Microbiota: The Conductor in the Orchestra of Immune-Endoctrine Communication. Clin Ther 2015; 37: 954-967 [PMID: 25846319 DOI: 10.1016/j.clinthera.2015.03.002]
12. Pellissier S, Bonaz B. The Place of Stress and Emotions in the Irritable Bowel Syndrome. Vitam Horm 2017; 103: 327-354 [PMID: 28061975 DOI: 10.1016/bs.vh.2016.09.005]
13. Brazowski R, Mazur-Bialy A, Pajdo R, Kwiecien S, Bilski J, Zwolińska-Wcisło M, Mach T, Brzozowski T. Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis. Curr Neuropharmacol 2016; 14: 892-900 [PMID: 27040468 DOI: 10.2174/1570159X14666160404124127]
14. Keightley PC, Kolosis NA, Talley NJ. Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes. Aust N Z J Psychiatry 2015; 49: 207-214 [PMID: 25710826 DOI: 10.1177/0004867415609891]
15. Israeli E, Hershovich T, Berentsen E, Zannielli G, Wegrower D, Weiss O, Chevion M, Goldin E. The effect of restraint stress on the normal colon and on intestinal inflammation in a model of experimental colitis. Dig Dis Sci 2008; 53: 88-94 [PMID: 17565472 DOI: 10.1007/s10620-007-9827-z]
16. Chowdry HS, Jessop DS, Lightman SL. Substance P stimulates arginine vasopressin and inhibits adenocorticotropin release in vivo in the rat. Neuroendocrinology 1999; 50: 90-93 [PMID: 1697661 DOI: 10.1159/0000125544]
17. Söderholm JD. Effect of stress on intestinal mucosal functions. In: Johnson LR, Ghishan FK, Kaunitz JD, Merchant BL, Said HM, Wood JD. Physiology of the Gastrointestinal Tract. 6th ed. In: Elsevier Inc 2012, 1979-2000 [DOI: 10.1161/B978-0-8-38206-6-00074-9]
18. Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23: 6693-6627 [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6693]
19. Ash C, Mueller K. Manipulating the Microbiota. Science 2016; 352: 530-531 [PMID: 27126033 DOI: 10.1126/science.352.6285.530]
20. Mayer EA, Tillisch K, Gupta A. Gut-brain axis and the microbiota. J Clin Invest 2015; 125: 926-938 [PMID: 25689247 DOI: 10.1172/JCI7634]
21. Bercik P, Denou E, Collini J, Jackson W, Lu J, Jury J, Deng Y, Bienenhassett P, Maci J, McCoy KD,
Sinagra E et al. Microbiota-gut-brain axis and its affect inflammatory bowel disease

Verdu EF, Collins SM. The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice. *Gastroenterology* 2011; 141: 599-609, 609.e1-609.e3. [PMID: 21683977 DOI: 10.1053/j.gastro.2011.04.052]

22 Collins SM, Kassam Z, Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. *Curr Opin Microbiol* 2013; 16: 240-245. [PMID: 23845749 DOI: 10.1016/j.mib.2013.06.004]

23 Carabotti M, Scirroco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Ann Gastroenterol* 2015; 28: 203-209. [PMID: 25830558]

24 Ait-Belgnaoui A, Colom A, Branioste V, Ramalho L, Marrot A, Carrier C, Houdeau E, Theodorou V, Tompkins T. Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. *Neurogastroenterol Motil* 2014; 26: 510-520. [PMID: 24372791 DOI: 10.1111/nmm.12295]

25 Kunze WA, Mao YK, Wang B, Huizinda JA, Ma X, Forsethy P, Bienenstock J. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. *J Cell Med* 2009; 13: 2261-2270. [PMID: 19210574 DOI: 10.1111/j.1529-432X.2009.00686.x]

26 Iyer LM, Aravind L, Coon SL, Klein DC, Koonin EV. Evolution of cell-cell signaling in animals: did late horizontal gene transfer from bacteria have a role? *Trends Genet* 2004; 20: 292-299. [PMID: 15219393 DOI: 10.1016/j.tig.2004.05.007]

27 Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshikura K, Koga Y, Sudo N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. *Am J Physiol Gastrointest Liver Physiol* 2012; 303: G1288-G1295. [PMID: 23064760 DOI: 10.1152/ajpgi.00341.2012]

28 Sobko T, Huang L, Midveldt T, Norin E, Gustafsson LE, Norman M, Janssen EA, Lundberg JO. Generation of NO by probiotic bacteria in the gastrointestinal tract. *Free Radic Biol Med* 2006; 41: 985-991. [PMID: 16934682 DOI: 10.1016/j.freeradbiomed.2006.06.020]

29 Verdú EF, Bercik P, Verma-Gandhi M, Huang XX, Blannterhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. *Gut* 2006; 55: 182-190. [PMID: 16185890 DOI: 10.1136/gut.2005.066100]

30 Saito T, Brunett NW. Protease-activated receptors: regulation of neuronal function. *Neuroendocrinology* 2005; 7: 79-99. [PMID: 16502040 DOI: 10.1158/1054-3884.JIMP-04-0305]

31 Biancheri P, Di Sabatino A, Corazza GR, McDonald TT. Proteases and the gut barrier. *Cell Tissue Res* 2013; 351: 269-280. [PMID: 23421210 DOI: 10.1007/s00441-012-1390-x]

32 González-Arancibia C, Escobar-Luna J, Bera-Bugueno E, Díaz-Zepeda C, González-Toro MP, Olavarria-Ramírez L, Zanelli-Massai F, Gotteland M, Bravo JA, Julio-Pieper M. What goes around comes around: novel pharmacological targets in the gut-brain axis. *Therap Adv Gastroenterol* 2016; 9: 339-353. [PMID: 27134664 DOI: 10.1177/1756283616607166]

33 Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. *Gastroenterology* 2009; 136: 2003-2014. [PMID: 19457424 DOI: 10.1053/j.gastro.2009.01.075]

34 Lepage P, Colombeau J, Marteau P, Sime-Ngando T, Doré J, Leclerc M. Dysbiosis in inflammatory bowel disease: a role for bacteriophages? *Gut* 2008; 57: 425-425. [PMID: 18260505 DOI: 10.1136/gut.2007.134668]

35 Frank DN, St Amand AL, Feldman RA, Boeder EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. *Proc Natl Acad Sci USA* 2007; 104: 13780-13785. [PMID: 17699621 DOI: 10.1073/pnas.0706625104]

36 Chassaing B, Rolhion N, de Vallée A, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing microbial community associated with disease activity in patients with inflammatory bowel disease. *Gut* 2008; 57: 424-425. [PMID: 18260504 DOI: 10.1136/gut.2007.134662]

37 Sokal H, Pigneur B, Watterlot L, Lukhadi O, Bermúdez-Humarán LG, Gratadoux JJ, Binz S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blugeon S. Dysbiosis and anti-inflammatory properties of microbial communities in IBD. *Gut* 2016; 65: 966-975. [PMID: 24891104 DOI: 10.1136/gutjnl-2015-310005]

38 Proksch M, Bendsen F, Vind I, Petersen AM, Gluud LL. The association between the gut microbiota and the inflammatory bowel disease: a role for bacteriophages? *J Clin Invest* 2011; 121: 966-975. [PMID: 21353467 DOI: 10.1172/JCI44632]

39 Sinagra E et al. Microbiota-gut-brain axis and its affect inflammatory bowel disease: a role for bacteriophages? *F1000Prime Rep* 2015; 7: 44. [PMID: 26097717 DOI: 10.12703/P7-44]

40 Malon P, McKay D, Kirk S, Gardiner P. Probiotics for induction of remission in ulcerative colitis. *World J Gastroenterol* 2016; 51: 1407-1415. [PMID: 27687333 DOI: 10.3748/wjg.v22.i3.1078]
Sinagra E et al. Microbiota-gut-brain axis and its affect inflammatory bowel disease

Cochrane Database Syst Rev 2007; CD005573 [PMID: 17943867 DOI: 10.1002/14651858.CD005573.pub2]

Lichtenstein L, Avni-Biron I, Ben-Bassat O. The current place of probiotics and prebiotics in the treatment of pouchitis. Best Pract Res Clin Gastroenterol 2016; 30: 73-80 [PMID: 27048895 DOI: 10.1016/j.bpcg.2016.02.003]

Casellas F, Borrel N, Torrejon A, Varela E, Antolín M, Guarnier F, Malalgadela JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007; 25: 1061-1067 [PMID: 17439507 DOI: 10.1111/j.1365-2036.2007.03298.x]

Benjamin JL, Hedin CR, Koutsoumpa A, Ng SC, McCrane NE, Hart AL, Kam MA, Anderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO. Randomised, double-blind, placebo-controlled trial of fructo-oligo-saccharides in active Crohn's disease. Gut 2011; 66: 923-929 [PMID: 21262918 DOI: 10.1136/gut.2010.232025]

Lindsay JO, Whelan K, Stagg AJ, Gabin P, Al-Hassi HO, Rayment N, Kam MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligo-saccharides in patients with Crohn's disease. Gut 2006; 55: 348-355 [PMID: 16162800 DOI: 10.1136/gut.2005.074971]

Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reischl W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6 [PMID: 25857665 DOI: 10.1053.j.gastro.2015.04.001]

Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10: 66 [PMID: 22747645 DOI: 10.1186/1741-7015-10-66]

Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-342 [PMID: 24751956 DOI: 10.1038/nri3661]

Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 2014; 20: 160-172 [PMID: 24106265 DOI: 10.1177/1073858413494460]

Dunn AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000; 917: 608-617 [PMID: 11268389 DOI: 10.1111/j.1749-6632.2000.tb05426.x]

Miller AH, Pariente CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999; 461: 107-116 [PMID: 10442170 DOI: 10.1007/978-0-387-98790-8_7]

Pariente CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464-466 [PMID: 18675469 DOI: 10.1016/j.tins.2008.06.006]

O'Mahony SM, Clarke G, Dinan TG, Cryan JF. Early-life adversity and brain development: Is the microbiome a missing piece of the puzzle? Neuroscience 2017; 342: 37-54 [PMID: 26432952 DOI: 10.1016/j.neuroscience.2015.09.008]

Reber SO, Birkeneder L, Veenema AH, Obermeier F, Falk W,Straub RH, Neumann ID. Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms. Endocrinology 2007; 148: 670-682 [PMID: 17110427 DOI: 10.1212/en.2006-09983]

Reber SO, Obermeier F, Straub RH, Veenema AH, Neumann ID. Aggravation of DSS-induced colitis after chronic subordinate colony (CSC) housing is partially mediated by adrenal mechanisms. Stress 2008; 11: 225-234 [PMID: 18463469 DOI: 10.1080/1025389071733351]

Vicario M, Guirarte M, Alonso C, Yang P, Martinez C, Ramos L, Lobo B, González A, Guílal M, Pigrau M, Saperas E, Azpiroz F, Santos J. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. Brain Behav Immun 2010; 24: 1166-1175 [PMID: 20600818 DOI: 10.1016/j.bbi.2010.06.002]

Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533 [PMID: 12876555 DOI: 10.1038/nri132]

Hathaway CA, Appleyard CB, Percy WH, Williams JL. Experimental colitis increases blood-brain barrier permeability in rabbits. Am J Physiol 1999; 276: G1174-G1180 [PMID: 10303008 DOI: 10.1152/ajpgi.1999.276.5.G1174]

Natah SS, Mouhate A, Pittman QJ, Sharkey KA. Disruption of the blood-brain barrier during TNBS colitis. Neurogastroenterol Motil 2005; 17: 433-446 [PMID: 15916631 DOI: 10.1111/j.1365-2922.2005.00654.x]

Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ. Microglial activation and TNFα production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci USA 2008; 105: 17511-17516 [PMID: 18955701 DOI: 10.1073/pnas.0806862105]

Medhö B, Prakash A, Avti PK, Chakrabarti A, Khanduja KL. Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-α in a rat model. J Pharm Pharmacol 2009; 61: 1359-1364 [PMID: 19814869 DOI: 10.1211/jpp.61.10.0013]

Wang K, Yuan CP, Wang W, Yang ZQ, Cui W, Mu LZ, Yue ZP, Hu ZM, Liu JX. Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis. World J Gastroenterol 2010; 16: 2252-2259 [PMID: 20458762 DOI: 10.3748/wjg.v16.i18.2252]

Batcke L, Detel D, Kucic N, Buljevic S, Pugel EP, Varden J. Neuroimmunomodulative properties of dipediptel peptide IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011; 112: 3322-3333 [PMID: 21751235 DOI: 10.1002/jcb.23261]

Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. PLoS J 2011; 25: 2711-2721 [PMID: 21551239 DOI: 10.1096/1086-0560]

Sans M, Kawachi S, Soriano A, Palacín A, Morise Z, Grisham MB, Panés J. Brain endothelial adhesion molecule expression in experimental colitis. Microcirculation 2001; 8: 105-114 [PMID: 11579790 DOI: 10.1080/136574022]

Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013; 144: 36-49 [PMID: 23069370 DOI: 10.1016/j.gastro.2012.10.007]

Tachè Y, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007; 117: 33-40 [PMID: 17200704 DOI: 10.1172/JCI30085]

Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci 2018; 12: 49 [PMID: 29467611 DOI: 10.3389/fnins.2018.00049]

Santer S, Saunders PR, Hanssen NP, Yang PC, Yates D, Groot JA, Perdue MH. Corticotropin-releasing
hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol 1999; 277: G391-G399 [PMID: 10444454 DOI: 10.1152/ajpgi.1999.277.2.G391]

72 Bailey MT, Engler H, Sheridan JF. Stress induces the translocation of cutaneous and gastrointestinal microbiota to secondary lymphoid organs of C57BL/6 mice. J Neuroimmunol 2006; 171: 29-37 [PMID: 16253348 DOI: 10.1016/j.neuroim.2005.09.008]

73 Lyte M, Li W, Opitz N, Gaykema RP, Goehler LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav 2006; 89: 330-337 [PMID: 16887134 DOI: 10.1016/j.physbeh.2005.11.005]

74 Vidal A, Gómez-Gil E, Sans M, Portella MJ, Salameño M, Piqué JM, Panés J. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis 2008; 14: 977-983 [PMID: 18275078 DOI: 10.1002/ibd.20383]

75 Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholt B, Samuelsson A, Hibberd ML, Forsberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047-3052 [PMID: 21282636 DOI: 10.1073/pnas.1010529108]

76 Ananthakrishnan AN, Khalili H, Pan A, Higuchi LM, de Silva P, Richter JM, Fuchs CS, Chan AT. Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. Clin Gastroenterol Hepatol 2013; 11: 57-62 [PMID: 22944733 DOI: 10.1016/j.cgh.2012.08.032]

77 Million M, Taché Y, Anton P. Susceptibility of Lewis and Fischer rats to stress-induced worsening of TNB-colitis: protective role of brain CRF. Am J Physiol 1999; 276: G1027-G1036 [PMID: 10198347 DOI: 10.1152/ajpgi.1999.276.4.G1027]

78 Cao SS. Cellular Stress Responses and Gut Microbiota in Inflammatory Bowel Disease. Gastroenterol Res Pract 2018; 2018: 792664 [PMID: 30025758 DOI: 10.1155/2018/792664]

79 Lobionda S, Sittipo P, Kwon HY, Lee YK. The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors. Microorganisms 2019; 7: [PMID: 31430948 DOI: 10.3390/microorganisms7080521]

80 Galley JD, Mackos AR, Varajaj VA, Bailey MT. Stressor exposure has prolonged effects on colonic microbial community structure in Citrobacter rodentium-challenged mice. Sci Rep 2017; 7: 45012 [PMID: 28344333 DOI: 10.1038/srep45012]

81 Mackos AR, Eubank TD, Parry NM, Bailey MT. Probiotic Lactobacillus reuteri attenuates the stressor-enhanced severity of Citrobacter rodentium infection. Infect Immun 2013; 81: 3253-3263 [PMID: 23985531 DOI: 10.1128/IAI.00278-13]

82 Bharwani A, Mian MF, Foster JA, Surette MG, Gienest J, Forsythe P. Structural & functional consequences of chronic psychosocial stress on the microbiome & host. Psychoneuroendocrinology 2016; 63: 217-227 [PMID: 26479188 DOI: 10.1016/j.psyneuen.2015.10.001]

83 Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, Wu Q, You L, Wang Y, Lin Y, Li X, Wang Y, Bian JS, Sun D, Kong L, Birnbaumer L, Yang Y. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci USA 2018; 115: E2960-E2969 [PMID: 29531080 DOI: 10.1073/pnas.1720696115]

84 Dufly LC, Zielcezny MA, Marshall JR, Byers TE, Weiser MM, Phillips JF, Calkins BM, Ogra PL, Graham GS. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med 1991; 17: 101-110 [PMID: 1932842 DOI: 10.1080/08964289.1991.9937553]

85 Szigethy EM, Youk AO, Benhayon D, Fairclough DL, Newara MC, Kirshner MA, Bujoreanu SI, Peterson S, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2014; 20: 3072-3080 [PMID: 25016410 DOI: 10.1002/ibd.22514]

86 Falgout JD, Mackos AR, Varajaj VA, Bailey MT. Stressor exposure has prolonged effects on colonic microbial community structure in Citrobacter rodentium-challenged mice. Sci Rep 2017; 7: 45012 [PMID: 28344333 DOI: 10.1038/srep45012]

87 Mackos AR, Eubank TD, Parry NM, Bailey MT. Probiotic Lactobacillus reuteri attenuates the stressor-enhanced severity of Citrobacter rodentium infection. Infect Immun 2013; 81: 3253-3263 [PMID: 23985531 DOI: 10.1128/IAI.00278-13]

88 Ghia JE, Blemerhassett P, Deng Y, Verdu EF, Khan WJ, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009; 136: 2280-2288.e1-4 [PMID: 19272381 DOI: 10.1053/j.gastro.2009.02.069]

89 Pichota-Polaneczky A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol 2014; 387: 605-620 [PMID: 24798211 DOI: 10.1007/s00210-014-0498-3]

90 Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006; 12: 38-46 [PMID: 16374257 DOI: 10.1002/ibd.20019.1009769]
Sinagra E et al. Microbiota-gut-brain axis and its affect inflammatory bowel disease

98 Ennaifer R, Elleuch N, Cheikh M, Hefaiedh R, Romdhane H, Ben Nejma H, Bellahj N. Risk factors of psychological disorders in inflammatory bowel disease in a tunisian survey. Results of a cross-sectional study. *Tunis Med* 2014; 92: 723-726 [PMID: 25879556]

99 Panara AJ, Yarur AJ, Rielers B, Proksell S, Deshpande AR, Abreu MT, Sussman DA. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. *Aliment Pharmacol Ther* 2014; 39: 802-810 [PMID: 24588323 DOI: 10.1111/apt.12669]

100 Casellas F, López-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. *Qual Life Res* 2002; 11: 775-781 [PMID: 12482161]

101 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. *Aliment Pharmacol Ther* 2013; 38: 44-51 [PMID: 23668698 DOI: 10.1111/apt.12335]

102 Camaño RJ, Ziegler R, Bégré S, Schoepfer AM, von Kanel R; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. *Digestion* 2009; 80: 129-139 [PMID: 19657191 DOI: 10.1159/000268087]

103 Graff LA, Walker JR, Clara I, Lix L, Miller N, Rogata L, Rawshorne P, Bernstein CN. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. *Am J Gastroenterol* 2009; 104: 2959-2969 [PMID: 19755973 DOI: 10.1111/j.1572-0241.2009.02529.x]

104 Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. *Am J Gastroenterol* 2010; 105: 1994-2002 [PMID: 20372115 DOI: 10.1038/ajg.2010.140]

105 Targowski LE, Sexton KA, Bernstein MT, Beatie B, Sargent M, Walker JR, Graff LA. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. *Am J Gastroenterol* 2015; 110: 1001-12; quiz 1013 [PMID: 26077178 DOI: 10.1016/j.amjgastro.2015.09.009]

106 Agostoni A, Filippini N, Benuzzi F, Bertani A, Scarcelli A, Leonci C, Farinelli V, Riso D, Tambasco R, Calabrese C, Rizzello F, Gionchetti P, Ercolani M, Nichelli F, Campieri M. Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. *J Behav Med* 2013; 36: 477-487 [PMID: 22752251 DOI: 10.1007/s10865-012-9441-1]

107 Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. *Gastroenterology* 2018; 154: 1635-1646.e3 [PMID: 29369681 DOI: 10.1053/j.gastro.2018.01.027]

108 Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfeld GM, Hold G, Qurashi MN, Kinnors J, Smith H, Tushoy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. *Gut* 2016; 65: 330-339 [PMID: 26388272 DOI: 10.1136/gutjnl-2015-309990]

109 Moran C, Shananah F. Editorial: probiotics and IBS - where are we now? *Aliment Pharmacol Ther* 2014; 40: 318 [PMID: 25040711 DOI: 10.1111/apt.12836]

110 Pinna DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? *Neurogastroenterol Motil* 2015; 27: 19-29 [PMID: 25424663 DOI: 10.1111/nmo.12479]

111 Sinagra E, Tomaselio G, Cappello F, Leone A, Cottone M, Bellavia M, Rossi F, Facella T, Damiani P, Zeezny MN, Damiani A, Abruzzo A, Damiano G, Palumbo VD, Cocchi M, Jurias J, Spinelli G, Lo Monte AI, Raimondo D. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. *J Biol Regul Homeost Agents* 2013; 27: 919-933 [PMID: 24382173]

112 Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. *Cochrane Database Syst Rev* 2009; CD006873 [PMID: 19821389 DOI: 10.1002/14651858.CD006873.pub2]

113 Wasielski A, Zielinska M, Storr M, Ficyna J. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; 21: 1674-1682 [PMID: 25822014 DOI: 10.1097/MIB.0000000000000364]

114 Kris W, Eric P, Pokrotniok J, Lukás M, Fisza B, Káská M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004; 53: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]

115 Shadnoush M, Shaker Hosseini R, Mehrabi Y, Delpisheh A, Alipoor E, Faghfoori Z, Mohammadpour N, Zarringhalam Moghadam J. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. *Iran J Pharm Res* 2013; 12: 929-936 [PMID: 24523774]

116 Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J Am Coll Nutr* 2003; 22: 56-63 [PMID: 12699115 DOI: 10.1080/07315724.2003.10719276]

117 Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Dal Re E, Faghfoori Z, Mohammadpour N, Zarringhalam Moghadam J. Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. *Iran J Pharm Res* 2013; 12: 929-936 [PMID: 24523774]

118 Kuissa J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. *Aliment Pharmacol Ther* 2003; 17: 509-515 [PMID: 12622778 DOI: 10.1046/j.1365-2657.2003.01465.x]

119 Giovannetti P, Rizzello F, Venturi A, Brigidip P, Matteuzzi D, Bazzocchi G, Poggio G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2004; 19: 305-309 [PMID: 15030365 DOI: 10.1046/j.1365-2036.2003.02927.x]

120 Giovannetti P, Rizzello F, Venturi A, Brigidip P, Matteuzzi D, Bazzocchi G, Poggio G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Aliment Pharmacol Ther* 2003; 18: 1202-1209 [PMID: 12730861 DOI: 10.1046/j.1365-2657.2003.01017-9]

121 Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* 1995; 108: 975-982 [PMID: 7698613 DOI: 10.1016/0016-5085(95)90192-2]
123 Muccioli GG, Naslain D, Blüchert F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392 [PMID: 20664638 DOI: 10.1038/msb.2010.46]

124 Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009; 15: 454-462 [PMID: 19235891 DOI: 10.1002/ibd.20242]

125 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573 [PMID: 23823891 DOI: 10.1126/science.1241165]

126 Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242-249 [PMID: 15647189 DOI: 10.1136/gut.2004.044834]

127 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573 [PMID: 23823891 DOI: 10.1126/science.1241165]

128 Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242-249 [PMID: 15647189 DOI: 10.1136/gut.2004.044834]

129 Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009; 15: 454-462 [PMID: 19235891 DOI: 10.1002/ibd.20242]

130 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573 [PMID: 23823891 DOI: 10.1126/science.1241165]

131 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

132 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

133 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

134 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

135 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

136 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

137 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

138 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

139 Stede H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]
